Skip to content

Lecanemab: what the new five-year results mean for the Alzheimer’s drug in the UK

11-minute read | 17/11/2026

News
Inna OleksiienkoEditorial Contributor

New results suggest that the benefits of the Alzheimer's drug lecanemab may keep building the longer people take it, over five years of treatment. The findings were shared on 16 November 2026.

Lecanemab is licensed in the UK, but it isn't available on the NHS. Here we explain what the new results show, why they matter, and what they could mean for people in the early stages of Alzheimer's and their families.

What was announced

On 16 November 2026, the drug's makers, Eisai and Biogen, presented new results at the Clinical Trials on Alzheimer's Disease conference, held in Boston and online. The results followed 351 people who had taken lecanemab without a break for five years. This five-year period includes the original 18-month trial, called Clarity AD, and another three and a half years in a follow-up study.

After the original trial, 95% of people who completed it chose to carry on in the follow-up study, where everyone took lecanemab. So there was no placebo group to compare with at five years. Instead, the makers compared them with outside research data, from studies called ADNI and BioFINDER, on how Alzheimer's usually progresses.

Clarity AD was an international trial, run at 235 sites across North America, Europe and Asia. The five-year group is made up of people from this trial who carried on in the follow-up study.

The makers reported that:

  • The benefit kept growing over time. The gap between people taking lecanemab and the comparison data got bigger at three, four and five years.
  • Fewer people moved to a later stage. After five years, around six in ten people taking lecanemab (61.9%) had moved to the next stage of Alzheimer's. In the comparison data, it was nearly eight in ten (77.5%).
  • Fewer people reached moderate or severe dementia. Around three in ten people taking lecanemab (31%) did, compared with around five in ten (48.7%) in the comparison data.
  • No new safety findings. The companies reported no new safety findings in this group over five years. This doesn't rule out longer-term risks.

These results come from a conference presentation and the companies' own announcement, rather than a paper in a medical journal.

What lecanemab is and who it's for

Lecanemab (brand name Leqembi) was the first disease-modifying treatment approved for use in the UK for early Alzheimer's, meaning it aims to slow the disease rather than only ease symptoms. It binds to amyloid, a protein that builds up in the brain in people with Alzheimer's, to help clear it.

In the original 18-month trial, called Clarity AD, 1,795 people with early Alzheimer's took either lecanemab or a dummy treatment (placebo). Lecanemab slowed decline by 27% compared with the placebo. NICE estimated this means slowing progression by about four to six months.

It's an important step, but lecanemab isn't a cure, and it won't be suitable for everyone. Here's who it's licensed for and what treatment involves:

Why we're only hearing this now

Long-term results take years to collect. The original trial lasted 18 months, and researchers have shared updates from the follow-up study as each new year of data came in.

  • 18 months: the original trial showed lecanemab slowed decline.
  • Three years: results showed the benefit was still building.
  • Four years: results shared in 2025 showed people continued to benefit.
  • Five years: the latest results, shared on 16 November 2026.

Is it available on the NHS?

Not yet. Lecanemab has been licensed in the UK since August 2024. But for the NHS in England and Wales to offer it, NICE needs to recommend it. At the moment, people can only get it privately.

Here's how it has gone so far:

A similar drug, donanemab (brand name Kisunla), was paused in the same way. NICE has estimated that around 70,000 adults in England would have been eligible for treatment with one of these drugs.

England, Wales, Scotland and Northern Ireland

The drug isn't available on the NHS anywhere in the UK. But the decision isn't made the same way in every country.

CountryWho decidesWhere things stand

England

NICE

Not recommended. The assessment is paused while Eisai and NHS England discuss a price.

Wales

Same as England.

Northern Ireland

NICE decisions are normally adopted

Same as England.

Scotland

Scottish Medicines Consortium (SMC)

Not recommended. The SMC said no in February 2025, and again in July 2025 after a second review.

In Scotland, the SMC pointed to the high cost and uncertainty about how well it works. It said it would welcome a resubmission that deals with those uncertainties. Donanemab was also not recommended in Scotland in February 2026.

Can people get lecanemab privately?

Because lecanemab is licensed in the UK, it can be prescribed outside the NHS. Alzheimer's Society says it's available through some private health providers.

It's a specialist treatment with several steps before anyone can start it:

  • Specialist assessment. UK specialists recommend that people are first assessed in hospital-based services, then referred to a specialist centre to confirm the diagnosis, have genetic counselling and testing for APOE4, and get a decision from a team of specialists on whether it's suitable.
  • Registration. The MHRA said that starting treatment goes through a central registration system, as part of a controlled access programme.
  • Ongoing treatment. It's given as a drip every two weeks, with regular brain scans to check for side effects.

What it costs. The Scottish Medicines Consortium estimated the price of the drug itself at around £21,320 a year. Private treatment costs more, because it also includes specialist tests, regular infusions and brain scans. In July 2025, Alzheimer's Research UK estimated private treatment at £60,000 to £80,000 a year, and said costs vary between providers.

These figures are general estimates, not a recommendation. Each provider sets its own prices, which may have changed since these estimates were published.

What the NHS has said, and when it could be available

Right now, nothing has changed for patients. The new five-year results don't change the drug's NHS status, and it's still only available privately.

Here's what the NHS and the government have said:

Leading dementia specialists and charities are calling for NHS access to these drugs. They're also calling for a maximum 18-week wait for a dementia diagnosis, so people can get treatment as soon as possible.

If the NHS approves it, how soon could people get it?

No date for a decision has been announced. If NICE does recommend lecanemab:

Even then, it may take time for everyone eligible to get it. In June 2025, Alzheimer's Society said that even if the drugs were available on the NHS straight away, too many people couldn't get them because the health system isn't ready to deliver them.

In the US, a version of lecanemab that's injected under the skin has been approved for both starting and continuing treatment. In the US, this lets people have injections at home instead of hospital infusions. In July 2026, UK regulators were expected to decide on it later in the year. US approval doesn't mean it will be approved in the UK.

Why the results matter

One of the biggest questions about lecanemab has been whether its benefits last. The original trial lasted 18 months, and the lack of long-term evidence was one of the reasons NICE gave for its decision. The makers say the new results show the benefit continuing to build over time.

NICE's own committee accepted that any slowing of the disease would be meaningful, because it could mean more time socialising, driving and being independent, and needing less day-to-day help from family.

There are important limits to keep in mind:

  • The comparison wasn't with a placebo group. After the first 18 months, everyone in the follow-up study took lecanemab. So the makers compared them with outside data on how the disease usually progresses.
  • The results haven't been published in a medical journal. They come from a conference presentation and the companies' announcement.
  • The five-year group is the 351 people who stayed on treatment for the whole period.
  • It doesn't change the NHS position yet. The drug is still only available privately.

What happens next

Price talks between Eisai and NHS England began in July 2026, and no date for a decision has been announced. It's too early to say whether these new results will affect the outcome.

If you have questions about memory problems or about this treatment, a GP is the best person to speak to.

In October 2026, the government announced a £48 million partnership to speed up dementia research and help new treatments reach patients faster.

This article is for general information only and isn't medical advice. Speak to a GP or specialist about any treatment.

This article reflects the situation as of 17 November 2026.

Elder is an introductory agency and therefore does not direct, control, monitor or oversee the ongoing delivery of care. This article is for general information only and is not a substitute for professional advice, which should be sought when appropriate.